AU2010220058B2 - Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome - Google Patents

Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome Download PDF

Info

Publication number
AU2010220058B2
AU2010220058B2 AU2010220058A AU2010220058A AU2010220058B2 AU 2010220058 B2 AU2010220058 B2 AU 2010220058B2 AU 2010220058 A AU2010220058 A AU 2010220058A AU 2010220058 A AU2010220058 A AU 2010220058A AU 2010220058 B2 AU2010220058 B2 AU 2010220058B2
Authority
AU
Australia
Prior art keywords
extract
organic solvent
group
biologically active
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010220058A
Other languages
English (en)
Other versions
AU2010220058A1 (en
Inventor
Venkata Krishna Raju Alluri
Kiran Bhupathiraju
Ganga Raju Gokaraju
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Trimurtulu Golakoti
Krishanu Sengupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Nutra Pvt Ltd
Original Assignee
Laila Nutra Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutra Pvt Ltd filed Critical Laila Nutra Pvt Ltd
Publication of AU2010220058A1 publication Critical patent/AU2010220058A1/en
Application granted granted Critical
Publication of AU2010220058B2 publication Critical patent/AU2010220058B2/en
Assigned to LAILA NUTRA PRIVATE LIMITED reassignment LAILA NUTRA PRIVATE LIMITED Request for Assignment Assignors: LAILA NUTRACEUTICALS
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
AU2010220058A 2009-02-02 2010-02-01 Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome Active AU2010220058B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN224/CHE/2009 2009-02-02
IN224CH2009 2009-02-02
PCT/IN2010/000053 WO2010100653A2 (en) 2009-02-02 2010-02-01 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome

Publications (2)

Publication Number Publication Date
AU2010220058A1 AU2010220058A1 (en) 2011-07-21
AU2010220058B2 true AU2010220058B2 (en) 2016-02-18

Family

ID=42710066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010220058A Active AU2010220058B2 (en) 2009-02-02 2010-02-01 Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome

Country Status (8)

Country Link
US (3) US9241964B2 (https=)
EP (1) EP2391374B1 (https=)
JP (1) JP2012516842A (https=)
KR (1) KR101682489B1 (https=)
CN (1) CN102292093B (https=)
AU (1) AU2010220058B2 (https=)
CA (1) CA2751227C (https=)
WO (1) WO2010100653A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ME01898B (me) 2008-08-12 2014-12-20 Zinfandel Pharmaceuticals Inc Metoda za identifikaciju faktora rizika od alchajmerove bolesti
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
PH12013500451A1 (en) * 2010-09-11 2013-05-20 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
JP5976271B2 (ja) * 2010-12-24 2016-08-23 クラシエホームプロダクツ株式会社 リパーゼ阻害剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
KR101508294B1 (ko) * 2012-07-05 2015-04-07 동국대학교 산학협력단 망고스틴 추출물 또는 감마, 알파 망고스틴을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 조성물
JP2014034562A (ja) * 2012-08-10 2014-02-24 Lotte Kenko Sangyo:Kk アディポネクチン産生促進剤
WO2014064609A2 (en) * 2012-10-23 2014-05-01 Piramal Enterprises Limited HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
US20140377386A1 (en) * 2013-06-19 2014-12-25 Access Business Group International Llc Plant-based inhibitors of ketohexokinase for the support of weight management
JP6511604B2 (ja) * 2013-07-10 2019-05-15 和久 前田 メタボリックシンドローム治療剤の製造方法
CN106361784B (zh) * 2015-07-24 2020-08-14 山酮新药开发股份有限公司 山竹果果壳萃取物用于治疗皮肤疾病的用途
TWI565472B (zh) * 2016-02-02 2017-01-11 基業生物科技股份有限公司 山竹組合物及其製備增進阿茲海默症患者學習能力與記憶的藥物及保健食品之用途
BR112018073483B1 (pt) * 2016-05-21 2022-08-23 Laila Impex Suplementos e composições dietéticas para a melhoria do desempenho físico e dos níveis de energia
CN111773208A (zh) * 2019-09-20 2020-10-16 厦门医学院 藤黄属果实萃取物γ-倒捻子素在制备降血糖及降血压的药物组合物中的应用
CN111758967B (zh) * 2020-07-15 2022-10-11 张兆熙 一种大鲵胶原蛋白肽组合物及其应用
CN118873430B (zh) * 2024-08-16 2025-04-04 诺德溯源(广州)生物科技有限公司 一种敏感肌适用的植物a醇祛皱紧致组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284134A2 (en) * 2000-05-26 2003-02-19 Shiseido Company Limited External skin preparations for suppressing sebum secretion
WO2007036900A2 (en) * 2005-09-30 2007-04-05 Piramal Life Sciences Limited Herbal composition for inflammatory disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3647054B2 (ja) * 1993-11-12 2005-05-11 御木本製薬株式会社 抗酸化剤
JPH09110688A (ja) * 1995-10-13 1997-04-28 Meiji Milk Prod Co Ltd 抗菌剤
FR2774905B1 (fr) * 1998-02-17 2000-06-09 Codif International Sa Utilisation d'une composition cosmetique comportant au moins une substance qui comprend un groupement pyrone
GB9921229D0 (en) * 1999-09-08 1999-11-10 Med Eq As Compositions
DE60309075D1 (de) * 2003-03-31 2006-11-23 Council Scient Ind Res Verfahren zur herstellung hypoglykämischer lebensmittel und formulierungen daraus
ES2559777T3 (es) * 2004-03-17 2016-02-15 Nestec S.A. Composiciones y métodos para reducir o prevenir la obesidad
JP4247154B2 (ja) * 2004-03-18 2009-04-02 有限会社 坂本薬草園 ＰＰＡＲγ活性化剤
JP5140231B2 (ja) * 2004-04-08 2013-02-06 株式会社ロッテ ＩκＢキナーゼ阻害剤
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
SI1931366T1 (sl) * 2005-09-30 2013-10-30 Piramal Enterprises Limited Zeliščni sestavek proti vnetnim motnjam
FR2908310B1 (fr) 2006-11-14 2009-07-10 Phytodia Produits agonistes de tgr5 et leurs applications
WO2008093848A1 (ja) 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284134A2 (en) * 2000-05-26 2003-02-19 Shiseido Company Limited External skin preparations for suppressing sebum secretion
US20060057229A1 (en) * 2000-05-26 2006-03-16 Shiseido Company, Ltd. External skin preparations for suppressing sebum secretion
WO2007036900A2 (en) * 2005-09-30 2007-04-05 Piramal Life Sciences Limited Herbal composition for inflammatory disorders
US20080254157A1 (en) * 2005-09-30 2008-10-16 Piramal Life Sciences Limited Herbal composition for inflammatory disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAFNA, A.R. et al: "Immunomodulatory Activity Of Methanol Extract Of Flower-Heads Of Sphaeranthus Indicus Linn", Ars Pharmaceutica, vol. 45, no. 3, January 2004, pages 281-291 *
PEDRAZA-CHAVERRI J. et al: "Medicinal properties of mangosteen (Garcinia mangostana)", Food And Chemical Toxicology, vol. 46, October 2008, pages 3227-3239 *
SHIRWAIKAR, A. et al., "In vitro antioxidant studies of Sphaeranthus indicus (Linn)", Indian Journal Of Experimental Biology, 1 December 2006, pages 993-996 *

Also Published As

Publication number Publication date
US10471114B2 (en) 2019-11-12
CA2751227A1 (en) 2010-09-10
EP2391374A4 (en) 2014-01-08
EP2391374A2 (en) 2011-12-07
JP2012516842A (ja) 2012-07-26
WO2010100653A8 (en) 2011-08-04
KR20110122158A (ko) 2011-11-09
US9241964B2 (en) 2016-01-26
EP2391374B1 (en) 2018-11-14
US20130136809A1 (en) 2013-05-30
CN102292093B (zh) 2015-01-28
CN102292093A (zh) 2011-12-21
AU2010220058A1 (en) 2011-07-21
KR101682489B1 (ko) 2016-12-05
WO2010100653A3 (en) 2010-11-04
US20160074457A1 (en) 2016-03-17
WO2010100653A2 (en) 2010-09-10
US20110280951A1 (en) 2011-11-17
CA2751227C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
AU2010220058B2 (en) Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome
US8703215B2 (en) Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases
Usai et al. Natural products for the treatment and management of diabetes mellitus in Zimbabwe-a review
Huang et al. Identification of compounds in adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) seed hull extracts that inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macrophages
US9345732B2 (en) Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
CN102612371B (zh) 含有多聚乙酰的提取物，分馏物和混合物及它们的应用
Peng et al. Bioactive compounds and bioactive properties of Chaga (Inonotus obliquus) mushroom: A review
US9849151B2 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
KR20200048057A (ko) 풀무치 추출물을 함유하는 항염증용 조성물
TW201943413A (zh) 含薑黃酮醇a及／或薑黃酮醇b之組合物
JP7095872B2 (ja) インターロイキン－３３産生抑制剤並びにインターロイキン－３３の増加に関連するアレルギー疾患の予防、治療又は抑制用の医薬品、医薬部外品、化粧料及び飲食品組成物
KR101487065B1 (ko) 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물
Wang et al. Research Progress on The Chemical Composition And Pharmacological Effects of Hawthron (Crataegus spp.): A Review
KR20240025853A (ko) 까마중 추출물을 유효성분으로 포함하는 면역증진 및 항비만용 조성물
HK1159520B (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
HK1159520A (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
KR20120037145A (ko) 필발 추출물, 이소플라본 및 ｌ-카르니틴을 함유하는 비만 또는 고지혈증 예방용 또는 개선용 조성물
KR101150485B1 (ko) 알코니아 트리플너비아 추출물을 함유하는 천식 또는 염증성 질환의 예방 및 치료용 약학적 조성물
KR20240037633A (ko) 작약 추출물을 유효성분으로 포함하는 대식세포 활성화 기반 선천성 및 후천성 면역반응 증진용 조성물
Usai¹t et al. treatment and management of
KR101557557B1 (ko) 엔드리케리아 아노말라 추출물을 포함하는 항비만 조성물
WO2012026771A2 (ko) 워크리아 인시그니스 추출물 또는 이의 분획물을 함유하는 염증성 질환 또는 천식의 예방 및 치료용 조성물
JP2011173905A (ja) 脂肪吸収抑制剤
JP2011178796A (ja) 脂肪吸収抑制剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LAILA NUTRA PRIVATE LIMITED

Free format text: FORMER OWNER(S): LAILA NUTRACEUTICALS